Helen Albert, Author at Labiotech.eu

About

Freelance science and health journalist with lots of experience writing about all aspects of life sciences and biotech. Recovering geneticist and evolutionary biologist. I am half German and half British and spend most of my time in Berlin while not hiding out in the Norfolk countryside in the UK. When not writing or editing, I like to spend my time taking photos, knitting, reading fiction, eating and making good food and travelling (when global conditions allow!).

Articles by Helen Albert

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 18 Dec 2019

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers that have a mutation in the Notch pathway, a group of proteins that helps cells communicate with each other. Many cancers have mutations in these […]

December 18, 2019 - 2 minutesmins - By Helen Albert

Expert Advice 11 Dec 2019

What Makes a Successful Biotech?

How does it feel to have co-developed the most successful drug in the world? This is something Jane Osbourn, now Chair of the Board at UK cell therapy biotech Mogrify, knows only too well. Early in her career, Osbourn was working as a postdoc in Cambridge and was persuaded to join a small, and at […]

December 11, 2019 - 12 minutesmins - By Helen Albert

Best in Biotech 3 Dec 2019

Industry Perspectives: Women in Biotech 2019

Women are underrepresented in biotech leadership roles in Europe, but things are slowly improving. We spoke to five senior women from the industry who told us their stories. At least half of life sciences and medical students across Europe are women. In the biotech and pharma industry, this statistic is similar in entry level jobs, […]

December 3, 2019 - 5 minutesmins - By Helen Albert

Expert Advice 5 Nov 2019

How Sweden’s Intellectual Property Law Boosts Biotech Innovation

Founding one biotech company and making a success of it is difficult enough, but Mathias Uhlén has founded 20. Not only is he a successful entrepreneur, he is also a professor at the Royal Institute of Technology in Stockholm and has accumulated more than €135M in research funding during his career. After doing a PhD […]

November 5, 2019 - 10 minutesmins - By Helen Albert

News and Trends 28 Oct 2019

AI-Driven Antibiotic Susceptibility Test Launched in Austria

Ares Genetics, an Austrian subsidiary of the German Curetis Group, has launched an early access program for its AI-driven antibiotic susceptibility test. The company, which focuses on molecular diagnostics, has a large, regularly updated database of genetic information on disease-causing microbes including strains showing antimicrobial resistance. The new test uses high-resolution sequencing to gain genetic […]

October 28, 2019 - 2 minutesmins - By Helen Albert

News and Trends 24 Oct 2019

British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech

London-based LabGenius has secured €8.9M in Series A funding, which the company plans to use to scale up its AI- and robotics-based drug development technology. LabGenius focuses on developing protein-based therapeutics using its ‘robot scientist’ EVA. “By transforming how these drugs are discovered, we have a shot at improving the lives of countless people,” said […]

October 24, 2019 - 2 minutesmins - By Helen Albert

Interview 23 Oct 2019

Channeling the Power of AI into Personalizing Medicine

Artificial intelligence has been much discussed of late, but will it really help us solve important problems like how to bring personalized medicine to as many patients as possible? Kate Hilyard, COO of Healx in Cambridge in the UK, believes it can. Getting a drug to clinical trials currently requires a large investment of both […]

October 23, 2019 - 7 minutesmins - By Helen Albert

News and Trends 15 Oct 2019

German Cancer Virotherapy Biotech Launches with €12M Series A

Abalos Therapeutics launches today with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds. Abalos, which is based in Essen, Germany, will focus on developing anti-cancer drugs with […]

October 15, 2019 - 2 minutesmins - By Helen Albert

20191008 Rheticus Evonik DEBO0495 freigegeben e1571095521515

News and Trends 15 Oct 2019

Artificial Photosynthesis-Driven Chemical Plant Launched in Germany

The German industrial giants Siemens and Evonik have launched a joint project to build and run a test plant to make valuable chemicals from water and waste carbon dioxide using bacteria — a process known as artificial photosynthesis. The test plant, which is currently under construction, will be based at Evonik’s site in Marl, Germany, […]

October 15, 2019 - 3 minutesmins - By Helen Albert

Expert Advice 8 Oct 2019

Why Good Teamwork is Key to Biotech Success

Teamwork is important throughout the development of a company, but never more so than in the early stages of a startup. Charlotte Edenius, co-founder and VP Business and Clinical development at Gesynta Pharma in Sweden, knows this well. With more than 20 years experience working in the industry, she knows how important it is for biotech leaders […]

October 8, 2019 - 10 minutesmins - By Helen Albert

Interview 18 Sep 2019

Why Communication is Key for Getting Ahead in Biotech

Many biotech founders and executives look to VC investors for advice and inspiration, but the attraction can go both ways. After more than a decade of investing in life science companies, Renee Aguiar-Lucander, now CEO of Calliditas Therapeutics, decided it was time to try sitting on the other side of the table. Prior to moving […]

September 18, 2019 - 11 minutesmins - By Helen Albert

Expert Advice 7 Sep 2019

Why Being in a New Field From the Start Can Pay Off in the Long Run

The field of immuno-oncology has expanded out of all recognition over the last few years. Having co-founded one of the first cancer immunotherapy biotechs — Immatics — CEO Harpreet Singh has seen it all happen. He plans to take advantage of the company’s head start to tackle solid tumors with its T-cell redirecting therapies. Singh […]

September 7, 2019 - 12 minutesmins - By Helen Albert

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Helen Albert

About

Articles by Helen Albert

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

What Makes a Successful Biotech?

Industry Perspectives: Women in Biotech 2019

How Sweden’s Intellectual Property Law Boosts Biotech Innovation

AI-Driven Antibiotic Susceptibility Test Launched in Austria

British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech

Channeling the Power of AI into Personalizing Medicine

German Cancer Virotherapy Biotech Launches with €12M Series A

Artificial Photosynthesis-Driven Chemical Plant Launched in Germany

Why Good Teamwork is Key to Biotech Success

Why Communication is Key for Getting Ahead in Biotech

Why Being in a New Field From the Start Can Pay Off in the Long Run

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Helen Albert

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!